• RBC Capital maintains an "Outperform" rating for Johnson & Johnson (NYSE:JNJ), raising its price target from $240 to $255.
• JNJ's stock surged by 52% from May 2025 to February 2026, driven by improved earnings and product achievements.
• The company's market capitalization stands at approximately $562.31 billion, with a notable increase in stock price and investor confidence.

Johnson & Johnson (NYSE:JNJ) is a global leader in the healthcare sector, known for its wide range of products in pharmaceuticals, medical devices, and consumer health. Competing with other major players like Pfizer and Merck, JNJ has shown remarkable performance in the market. On February 3, 2026, RBC Capital maintained its "Outperform" rating for JNJ, with the stock priced at $234.39. RBC Capital also raised its price target from $240 to $255, indicating strong confidence in the company's future prospects.

From May 2025 to February 2026, JNJ's stock surged by 52%, driven by improved earnings and product achievements. The company's revenue increased by 3.2%, with better margins, supported by innovation and strategic evolution. JNJ's current stock price is $233.39, reflecting a 1.14% increase, with a daily range between $230.48 and $235.20.

JNJ's market capitalization is approximately $562.31 billion, with a trading volume of 1,331,327 shares. The stock has reached a high of $235.24 and a low of $141.50 over the past year. The company's progress in legal matters and effective risk management have contributed to its positive performance and investor confidence.

RBC Capital's decision to maintain an "Outperform" rating and raise the price target to $255 indicates confidence in JNJ's future prospects. The company's strategic initiatives and product innovations are expected to continue driving growth. Investors are likely to keep a close eye on JNJ's performance as it navigates the competitive healthcare landscape.